Bioicus LAB
Life sciences needs discipline that moves your discovery forward, into a portfolio, a system, or a launch.
Ready to go to market?
Assets, systems, and leadership built with scientific rigour and commercial intent.
Expand your catalogue with assets built towards freedom to operate. Sourced by nature, powered by AI. Identification, validation, and commercial structuring of biological assets for licensing or partnership. First asset under management: BIQS001, a biosynthetic gene cluster on an active UK patent track.
Explore the science →As your organisation grows, documentation stops being manageable ad hoc. What you're missing are the systems that make protocols consultable and audit-ready as the team scales. DMS/QMS, workflow automation, and R&D operating systems, adjusted to your infrastructure and people.
See the cases →You have the science, the team, and the ambition. What's often missing is the commercial infrastructure: a roadmap, a go-to-market logic, someone who connects R&D decisions to market outcomes and executes them directly. Trusted by a Cambridge-based deep biotech.
Read how I think →A novel β-lactone biosynthetic gene cluster from an Atacama Desert extremophile. Three core biosynthetic enzymes. A ring-closing mechanism distinct from every characterised β-lactone cyclase known to date.
I surveyed 213 life sciences professionals for my MBA dissertation. The strongest predictor of ML adoption wasn't capability. It was trust.
Read →
Biology calls it obligate mutualism. Business calls it your best client. Both can end you.
Read →
Having a great scientific idea that doesn't stick with the market? The problem is rarely in the lab.
Read →Founder
Stalled discoveries become assets. That's what I do.
Serving life science companies across EMEA and LATAM markets.
My Bio →